Progenitor cell materials and methods
AssigneesLicentia Ltd., Ludwig Institute for Cancer Research
InventorsKari Alitalo, Vladimir Joukov
Life of this patent
Estimating the term…
Abstract
Provided are purified and isolated VEGF-C polypeptides capable of binding to at least one of KDR receptor tyrosine kinase (VEGFR-2) and Flt4 receptor tyrosine kinase (VEGFR-3); analogs of such peptides that have VEGF-C-like or VEGF-like biological activities or that are VEGF or VEGF-C inhibitors; polynucleotides encoding the polypeptides; vectors and host cells that embody the polynucleotides; pharmaceutical compositions and diagnostic reagents comprising the polypeptides; and methods of making and using the polypeptides.
Claims17
A method of isolating cells that co-express CD34 and VEGFR-3, comprising steps of:
- obtaining a biological sample from a human subject that contains cells;
- and
- separating cells that express both CD34 (CD34+) and VEGFR-3 (VEGFR-3+) from cells that do not co-express CD34 and VEGFR-3 in the sample, thereby isolating CD34+/VEGFR-3+ cells from the sample.
Dependencies are inferred from the claim text.